Synthetic small-molecule complement inhibitors

Current Opinion in Investigational Drugs

Volumn 5, Issue 11, 2004, Pages 1164-1173

  Holland, M Claire H ^a   Morikis, Dimitrios ^b   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of California Riverside   (United States)

Author keywords

Complement; Inflammation; Inhibitors; Peptides; Synthetic

Indexed keywords

3D 53; ACETYLCOMPSTATIN; ACETYLISOLEUCYL(CYSTEINYLVALINYLTRYPTOPHANYLGLUTAMYLASPARTYLTRYPTOPHANYLGLYCINYLALANYLHISTIDINYLARGINYLCYSTEINYL)THREONYLAMIDE; ACETYLISOLEUCYL(CYSTEINYLVALINYLTRYPTOPHANYLGLUTAMYLASPARTYLTRYPTOPHANYLGLYCINYLHISTIDINYLHISTIDINYLARGINYLCYSTEINYL)THREONYLAMIDE; ACETYLISOLEUCYL(CYSTEINYLVALINYLTYROSINYLGLUTAMYLSPARTYLTRYPTOPHANYLGLYCINYLALANYLHISTIDINYLARGINYLCYSTEINYL)THREONYLAMIDE; ACETYLISOLEUCYL(CYSTEINYLVALYLVALYLGLUTAMYLASPARTYLTRYPTOPHANYLGLYCYLALANYLHISTIDINYLARGINYLCYSTEINYL)THREONYLAMIDE; ACETYLLEUCYL(CYSTEINYLVALINYLVALINYLGLUTAMYLASPARTYLTRYPTOPHANYLGLYCYLHISTIDINYLTRYPTOPHANYLARGINYLCYSTEINYL)GLYCYLAMIDE; ANAPHYLATOXIN; ANTIINFLAMMATORY AGENT; APT 070; BINDING PROTEIN; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT INHIBITOR; COMPSTATIN; DIIMINOISODOLINE DERIVATIVE; ECULIZUMAB; FIBRIN; GRANULOCYTE COLONY STIMULATING FACTOR; MIROCOCEPT; MLN 2222; NGD 2000 1; OXYGEN; PEPTIDE DERIVATIVE; PEXELIZUMAB; PMX 53; POLYPEPTIDE; SB 290157; TP 10; TP 20; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLEMENT INHIBITION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HEMODYNAMICS; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INFLAMMATORY DISEASE; MOLECULAR WEIGHT; NEUTROPENIA; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; ARGININE; BENZHYDRYL COMPOUNDS; HUMANS; MEMBRANE PROTEINS; PEPTIDES, CYCLIC; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9144226972     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Holers MV, Lambris JD (Eds): Therapeutic Intervention in the Complement System. Humana Press, Totowa, NJ, USA (2000).
2. Sahu A, Lambris JD: Complement inhibitors: A resurgent concept in anti-inflammatory therapeutics. Immunopharmacology (2000) 49(1-2):133-148.
3. Morgan BP, Harris CL: Complement therapeutics; history and current progress. Mol Immunol (2003) 40(2-4):159-170.
4. Haynes DR, Harkin DG, Bignold LP, Hutchens MJ, Taylor SM, Fairlie DP: Inhibition of C5a-induced neutrophil chernotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem Pharmacol (2000) 60(5):729-733.
5. Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC: Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J (2003) 17(9):1003-1014.
6. Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, Gelfand JA: A new biologic role for C3a and C3a desArg: Regulation of TNF-α and IL-1β synthesis. J Immunol (1996) 156(9):3455-3460.
7. 2-dependent mechanisms. J Immunol (2003) 171(5):2631-2636.
8. Lappegård KT, Riesenfeld J, Brekke OL, Bergseth G, Lambris JD, Mollnes TE: Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production. Ann Thorac Surg (2004): in press.
9. Makrides SC: Therapeutic inhibition of the complement system. Pharmacol Rev (1998) 50(1):59-87.
10. Sahu A, Kay BK, Lambris JD: Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol (1996) 157(2):884-891.
11. Klepeis JL, Floudas CA, Morilkis D, Lambris JD: Predicting peptide structures using NMR data and deterministic global optimization. J Comput Chem (1999) 20(13):1354-1370.
12. Morikis D, Assa-Munt N, Sahu A, Lambris JD: Solution structure of compstatin, a potent complement inhibitor. Protein Sci (1998) 7(3):619-627.
13. Morikis D, Roy M, Sahu A, Troganis A, Jennings PA, Tsokos GC, Lambris JD: The structural basis of compstatin activity examined by .tructure-function-based design of peptide analogs and NMR. J Biol Chem (2002) 277(17):14942-14953.
14. Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD: Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol (2000) 165(5):2491-2499.
15. Morikis D, Lambris JD: Structural aspects and design of low-molecular-mass complement inhibitors. Biochem Soc Trans (2002) 30(6):1026-1036.
16. Sahu A, Morikis D, Lambris JD: Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol (2003) 39(10):557-566.
17. Lappegård KT, Fung M, Bergseth G, Riesenfeld J, Lambris JD, Videm V, Mollnes TE: Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg (2004) 77(3):932-941.
18. Furlong ST, Dutta AS, Coath MM, Gormley JJ, Hubbs SJ, Lloyd D, Mauger RC, Strimpler AM, Sylvester MA, Scott CW, Edwards PD: C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl α-ketoheterocycles. Immunopharmacology (2000) 48(2):199-212.
19. Soulika AM, Khan MM, Hattori T, Bowen FW, Richardson BA, Hack CE, Sahu A, Edmunds LH Jr, Lambris JD: Inhibition of heparin/protamine complex-induced complement activation by compstatin in baboons. Clin Immunol (2000) 96(3):212-221.
20. Morikis D, Soulika AM, Mallik B, Klepeis JL, Floudas CA, Lambris JD: Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. Biochem Soc Trans (2004) 32(1):28-32.
21. Soulika AM, Morikis D, Sarrias MR, Roy M, Spruce LA, Sahu A, Lambris JD: Studies of structure-activity relations of complement inhibitor compstatin. J Immunol (2003) 171(4 ):1881-1890.
22. Klepeis JL, Floudas CA, Morikis D, Tsokos CG, Argyropoulos E, Spruce L, Lambris JD: Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. J Am Chem Soc (2003) 125(28 ):8422-8423.
23. Mallik B, Lambris JD, Morikis D: Conformational interconversion in compstatin probed with molecular dynamics simulations. Proteins (2003) 53(1):130-141.
24. Ember JA, Jagels MA, Hugli TE: Characterization of complement anaphylatoxins and their biological responses. In: The Human Complement System in Health and Disease. Volanakis JE, Frank MM (Eds), Marcel Dekker Inc, New York, NY, USA (1998):241-284.
25. Wetsel RA, Kildsgaard J, Haviland DL: Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation. In: Therapeutic Interventions in the Complement System. Lambris JD, Holers MV (Eds), Humana Press, Totowa, NJ, USA (2000):113-153.
26. Stevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, Collins JA, Raffin TA: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest (1986) 77(6):1812-1816.
27. Pellas TC, Boyar W, van Oostrum J, Wasvary J, Fryer LR, Pastor G, Sills M, Braunwalder A, Yarwood DR, Kramer R, Kimble E et al Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo. J Immunol (1998) 160 11):5616-5621.
28. Heller T, Hennecke M, Baumann U, Gessner JE, zu Vilsendort AM, Baensch M, Boulay F, Kola A, Klos A, Bautsch W, Kohl J: Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol (1999) 163(2):985-994.
29. Sumichika H, Sakata K, Sato N, Takeshita S, Ishibuchi S, Nakamura M, Kamahori T, Ehara S, Itoh K, Ohtsuka T, Ohbora T et al: Identification of a potent and orally active non-peptide C5a receptor antagonist. J Biol Chem (2002) 277(51 ):49403-49407.
30. Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, Taylor SM: Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem (1999) 42(11):1965-1974.
31. Gerard NP, Gerard C: Complement in allergy and asthma. Curr Opin Immunol (2002) 14(6):705-708.
32. Kildsgaard J, Hollmann TJ, Matthews KW, Bian K, Murad F, Wetsel RA: Cutting edge: Targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol (2000) 165(10):5406-5409.
33. Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PB Jr, Tack BF, Wetsel RA: Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol (2001) 166 3):2025-2032.
34. Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, Zeng Z, Su K, Jurewicz AJ, Hertzberg RP, Bergsma DJ, Kumar C: Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem (1996) 271(34):20231-20234.
35. Kretzschmar T, Pohl M, Casaretto M, Przewosny M, Bautsch W, Klos A, Saunders D, Kohl J: Synthetic peptides as antagonists of the anaphylatoxin C3a. Eur J Biochem (1992) 210(1):185-191.
36. Grant EB, Guiadeen D, Singer M, Argentieri D, Hlasta DJ, Wachter M: Design, synthesis, and biological activity of diiminoisoindolines as complement component 3a antagonists. Bioorg Med Chem Lett (2001) 11(21):2817-2820.
37. Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, Settmacher B, Klos A, Erhard KF, Cousins RD, Sulpizio AC et al: Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol (2001) 166(10):6341-6348.
38. Huber-Lang MS, Sarma JV, McGuire SR, Lu KT, Padgaonkar VA, Younkin EM, Guo RF, Weber CH, Zuiderweg ER, Zetoune FS, Ward PA: Structure-function relationships of human C5a and C5aR. J Immunol (2003) 170(12):6115-6124.
39. Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, Van Riper G, Bondy S, Rosen H, Springer MS: Two-site binding of C5a by its receptor: An alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA (1994) 91(4 ):1214-1218.
40. Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S, Fischer P, Rosen H, Mumford RA, Springer MS: Development of C5a receptor antagonists: Differential loss of functional responses. J Immunol (1994) 153(9):4200-4205.
41. Wong AK, Finch AM, Pierens GK, Craik DJ, Taylor SM, Fairlie DP: Small molecular probes for G-protein-coupled C5a receptors: Conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. J Med Chem (1998) 41 18):3417-3425.
42. March DR, Proctor LM, Stoermer MJ, Sbaglia R, Abbenante G, Reid RC, Woodruff TM, Wadi K, Paczkowski N, Tyndall JDA, Taylor SM, Fairlie DP: Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol Pharmacol (2004) 65(4):868-879.
43. Reid RC, Abbenante G, Taylor SM, Fairlie DP: A convergent solution-phase synthesis of the macrocycle Ac-Phe-(Orn-Pro-D-Cha-Trp-Arg], a potent new antiinflammatory drug. J Org Chem (2003) 68(11):4464-4471.
44. Strachan AJ, Shiels IA, Reid RC, Fairlie DP, Taylor SM: Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Br J Pharmacol (2001) 134 8):1778-1786.
45. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, Videm V, Lappegard KT, Kohl J, Lambris JD: Essential role of the C5a receptor in E coll-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood (2002) 100(5):1869-1877.
46. Woodruff TM, Strachan AJ, Sanderson SD, Monk PN, Wong AK, Fairlie DP, Taylor SM: Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation (2001) 25(3):171-177.
47. Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes IJ, Lu KT, Guo RF, Neff TA, Padgaonkar VA, Lambris JD et al: Protection of innate immunity by C5aR antagonist in septic mice. FASEB J (2002) 16(12):1567-1574.
48. Paczkowski NJ, Finch AM, Whitmore JB, Short AJ, Wong AK, Monk PN, Cain SA, Fairlie DP, Taylor SM: Pharmacological characterization of antagonists of the C5a receptor. Br J Pharmacol (1999) 128 7):1461-1466.
49. Finch AM, Vogen SM, Sherman SA, Kirnarsky L, Taylor SM, Sanderson SD: Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. J Med Chem (1997) 40(6 ):877-884.
50. 68 in decapeptide agonists of C5a on C5a receptor binding, activation and selectivity. J Peptide Res (1999) 53(1):8-17.
51. Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB, Brodbeck RM, Krause JE, Choe HR, Gerard NP, Gerard C: C5L2, a nonsignaling C5A binding protein. Biochemistry (2003) 42(31):9406-9415.
52. 74. J Biol Chem (2002) 277(9 ):7165-7169.
53. Otto M, Hawlisch H, Monk PN, Muller M, Klos A, Karp CL, Kohl J: C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: Position 69 is the locus that determines agonism or antagonism. J Biol Chem (2004) 279(1):142-151.
54. Ratajczak J, Reca R, Kucia M, Majka M, Allendorf DJ, Baran JT, Janowska-Wieczorek A, Wetsel RA, Ross GD, Ratajczak MZ: Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood (2004) 103 6):2071-2078.
55. Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM: Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol (2004) 142(4):756-764.
56. Cianflone K, Xia Z, Chen LY: Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta (2003) 1609(2):127-143.
57. Erdei A, Andrasfalvy M, Peterfy H, Toth G, Pecht I: Regulation of mast cell activation by complement-derived peptides. Immunol Lett (2004) 92(1-2):39-42.
58. Flane AE, Mollnes TE, Videm V, Hovig T, Hogasen K, Mellbye OJ, Spruce L, Moore WT, Sahu A, Lambris JD: Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation (1999) 6(1):52-65.
59. Solvik UO, Haraldsen G, Fiane AE, Boretti E, Lambris JD, Fung M, Thorsby E, Mollnes TE: Human serum-induced expression of E-selectin on porcine aortic endothelial cells in vitro is totally complement mediated. Transplantation (2001) 72(12):1967-1973.
60. Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD: Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood (1998) 92(5):1661-1667.
61. Schmidt S, Haase G, Csomor E, Lutticken R, Peltroche-Llacsahuanga H: Inhibitor of complement, compstatin, prevents polymer-mediated MAC-1 up-regulation of human neutrophils independent of biomaterial type tested. J Biomed Mater Res (2003) 66A(3):491-499.
62. Klegeris A, Singh EA, McGeer PL: Effects of C-reactive protein and pentosan polysulphate on human complement activation. Immunology (2002) 106(3):381-388.
63. Andersson J, Nilsson Ekdahl K, Lambris JD, Nilsson B: Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials (2004):doi:10.1016/j.biomaterials.2004.05.011.
64. Short A, Wong AK, Finch AM, Haaima G, Shiels IA, Fairlie DP, Taylor SM: Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol (1999) 126(3):551-554.
65. Strachan AJ, Woodruff TM, Haaima G, Fairlie DP, Taylor SM: A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J Immunol (2000) 164(12):6560-6565.
66. Strachan AJ, Shiels IA, Reid RC, Fairlie DP, Taylor SM: Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Br J Pharmacol (2001) 134 8):1778-1786.
67. Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP, Taylor SM: Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum (2002) 46(9):2476-2485.
68. Arumugam TV, Shiels IA, Woodruff TM, Reid RC, Fairlie DP, Taylor SM: Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res (2002) 103(2):260-267.
69. Fleming SD, Mastellos D, Karpel-Massler G, Shea-Donohue T, Lambris JD, Tsokos GC: C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury. Clin Immunol (2003) 108(3):263-273.
70. Arumugam TV, Woodruff TM, Stocks SZ, Proctor LM, Pollitt S, Shiels IA, Reid RC, Fairlie DP, Taylor SM: Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol (2004) 40(6):934-941.
71. Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM: A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int (2003) 63(1):134-142.
72. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM: Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J Surg Res (2004) 116(1):81-90.
73. Harkin DW, Romaschin A, Taylor SM, Rubin BB, Lindsay TF: Complement C5a receptor antagonist attenuates multiple organ injury in a model of ruptured abdominal aortic aneurysm. J Vasc Surg (2004) 39(1):196-206.
74. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM: A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol (2003) 171(10):5514-5520.
75. Kim AH, Dimitriou ID, Holland MC, Mastellos D, Mueller YM, Altman JD, Lambris JD, Katsikis PD: Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. J Immunol (2004) 173(4): 2524-2529.
76. Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD: The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med (2003) 198(6):913-923.
77. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollman TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD et al: Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 112 11):1644-1654.
78. Abe M, Shibata K, Akatsu H, Shimizu N, Sakata N, Katsuragi T, Okada H: Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol (2001) 167(8):4651-4660.
79. Kondo C, Mizuno M, Nishikawa K, Yuzawa Y, Hotta N, Matsuo S: The role of C5a in the development of thrombotic glomerulonephritis in rats. Clin Exp Immunol (2001) 124(2):323-329.
80. Mizuno M, Nishikawa K, Okada N, Matsuo S, Ito K, Okada H: Inhibition of a membrane complement regulatory protein by a monoclonal antibody induces acute lethal shock in rats primed with lipopolysaccharide. J Immunol (1999) 162(9):5477-5482.